Deuruxolitinib Demonstrates Consistent Efficacy, Early Hair Regrowth in Severe Alopecia Areata

New data from 2 pooled phase 3 analyses suggest that deuruxolitinib (Leqselvi; Sun Pharma), an oral JAK1/JAK2 inhibitor, delivers both consistent efficacy across patient subgroups and early, meaningful hair regrowth in adults with severe alopecia areata (AA), reinforcing its role as a targeted treatment option for this challenging autoimmune condition.^1,2

The findings, presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, combine results from the THRIVE-AA1 and THRIVE-AA2 clinical trials, which evaluated deuruxolitinib in patients with at least 50% scalp hair loss.

Together, the analyses provide complementary insights into both the breadth and timing of treatment response, with one analysis demonstrating consistent efficacy of deuruxolitinib across patient populations, while the other highlighted its potential to deliver early improvements, an important consideration for both clinicians and patients managing expectations.

Historically, patients with AA may wait several months before seeing noticeable hair regrowth, even with treatment. The ability to achieve early signs of improvement may have meaningful implications for adherence, patient confidence, and overall treatment satisfaction. The studies also reinforce the clinical relevance of SALT-based endpoints. A SALT score of 20 or less is widely considered a meaningful indicator of treatment success, while lower thresholds such as SALT ≤10 reflect more complete regrowth.

One analysis focused on whether deuruxolitinib’s effectiveness varies across different patient populations. The pooled dataset included 867 patients, with 600 receiving deuruxolitinib 8 mg twice daily and 267 receiving placebo. At 24 weeks, 31% of patients treated with deuruxolitinib achieved a Severity of Alopecia Tool (SALT) score of 20 or less, indicating significant scalp hair regrowth, compared with just 0.8% of patients receiving placebo (P < .0001).¹

Importantly, this benefit was consistent across nearly all demographic and baseline characteristic subgroups evaluated. Patients experienced similar improvements regardless of age, sex, ethnicity, or geographic region, with statistically significant results favoring deuruxolitinib in most categories.

The treatment effect was also consistent across disease severity levels. Patients with both partial scalp hair loss and those with complete or near-complete hair loss at baseline saw meaningful improvements compared with placebo. Similarly, body weight did not appear to influence treatment response, suggesting broad applicability across patient types.

While efficacy was directionally favorable in Black patients, the difference did not reach statistical significance, likely due to the smaller sample size within this subgroup, highlighting the need for further research in more diverse populations.

A second analysis examined how quickly patients began to experience hair regrowth. These findings suggested that deuruxolitinib may deliver benefits earlier than traditionally expected in AA treatment. A statistically significant proportion of patients achieved a SALT score of 20 or less as early as Week 8. Specifically, 3.1% of patients receiving deuruxolitinib reached this milestone by Week 8, compared with just 0.4% of those on placebo (P = 0.0005).²

Response rates continued to increase over time, with the proportion of responders steadily rising through Week 24. By the end of the study period, nearly one-third of treated patients achieved clinically meaningful hair regrowth.

More stringent outcomes were also observed. By Week 12, 4.6% of patients treated with deuruxolitinib achieved a SALT score of 10 or less, representing near-complete scalp hair regrowth, while no patients in the placebo group reached this threshold. These responses continued to increase through Week 24.

While the results are encouraging, the researchers noted that some subgroup analyses were limited by smaller sample sizes, underscoring the need for continued investigation in more diverse patient populations. Still, the findings contribute to a growing body of evidence supporting JAK inhibition as a targeted approach in alopecia areata. By demonstrating both consistent efficacy and early response, deuruxolitinib may help address longstanding gaps in treatment for patients with severe disease.

References

1. Senna MM, King B, Mesinkovska NA, et al. Efficacy of deuruxolitinib across subgroups of patients with severe alopecia areata by demographic and baseline characteristics: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials. Presented at: 2026 AAD Annual Meeting; March 27-31, 2026; Denver, CO. Poster 74609.

2. Mostaghimi A, Senna M, King B, et al. Early improvement in scalp hair regrowth with deuruxolitinib in patients with severe alopecia areata: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials. Presented at: 2026 AAD Annual Meeting; March 27-31, 2026; Denver, CO. Poster 74582.